Industry News

Ipsen invested in containment and transfer equipment at Quotient’s Pennsylvania facility to support ongoing commercial production of a highly potent therapy for an ultra-rare ...

The collaboration is designed to align GMP RNA production with cell processing to reduce technical handoffs, accelerate clinical timelines, and strengthen U.S. supply chain.

The 46,000-square-foot Denton, Texas facility, part of the company’s $23 billion investment to expand its U.S. operations, is expected to be operational in 2028.

The new 30,000-square-foot facility in Bengaluru is designed to help biopharma developers shorten timelines and improve process control across multiple biologic modalities.

The 78,000-square-foot Costa Mesa facility is designed to support programs from cell line development through tech transfer into cGMP manufacturing.

The certification includes renewal for its oral solid dosage facility and first-time EU GMP approval for its oral liquid manufacturing site.

Construction is set to begin in spring 2026, with the two facilities in North Chicago expected to be fully operational in 2029 and supported by 300 new hires.

The deal expands GSK’s access to Bora’s global network, including its oral solid dose site in Maple Grove, Minnesota.

The CRDMO’s hiring spree aims to meet rising global demand and support expanded active pharmaceutical ingredient capacity across its India and international sites.

The collaboration will support development and GMP manufacturing of the allogeneic TED-A9 cell therapy program.

The move expands early-phase bioconjugates development and manufacturing capabilities at its Oss, Netherlands site.

The 300,000-square-foot site in Richfield adds cleanroom capacity and 300 jobs to support high-volume pharmaceutical device manufacturing.

The CDMO’s Leganés facility expansion adds clinical and pilot-scale capacity for potent oral solid dose programs.

The collaboration supports clinical production and regulatory work for a CRISPR-edited GD2 CAR-T program targeting solid tumors.

The new facility, part of J&J’s previously announced $55 billion U.S. investment, will expand domestic capacity and support its pipeline of advanced treatments.

The expansion is intended to add on-site commercial freeze-drying to support payload and linker manufacturing by early 2027.

The new facility in Sudair will serve as the company’s regional production hub for the Middle East and North Africa.

The deal pairs early-stage active pharmaceutical ingredient capabilities in Israel with Recipharm’s global late-stage and commercial manufacturing network.

The program will integrate AI-driven robotics into GMP cell therapy workflows to improve cycle times, durability, and scalability, according to the companies.

The new Shanghai facility will support commercialization and future allogeneic CAR T production.

The financing will support the commercial rollout of scalable nanoparticle manufacturing platforms for advanced therapeutics.

The facility in Suzhou, China, which also passed an EU audit in 2024, will support commercial production of the dengue vaccine for Brazil.

The partnership links early formulation and clinical supply with late-stage scale-up and commercial manufacturing.

The digital collaboration links clinical trial, registry, and medical record data to support study design and faster evidence generation.

The partnership links academic research with an integrated discovery platform to move programs toward clinical development.

The five-year plan includes local production and clinical R&D collaboration designed to strengthen pandemic preparedness in the country.

The $46 million investment targets U.S. manufacturing capacity for ropeginterferon alfa-2b used to treat polycythemia vera in adults.

The collaboration aims to onshore active pharmaceutical ingredient and finished dose production for the essential medicine used in hospitals nationwide.

The alliance looks to achieve shorter vein-to-vein timelines for cell and gene therapy and lower production costs.

The pharmaceutical company’s new lipid-based microbubble technology targets upstream cell selection and activation steps.